Table 1 Baseline demographics, clinical characteristics, mean striatal DaT SBR and BMP concentrations (adjusted for age and sex) in LRRK2, sPD and HC cohorts.

From: LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

a Comparison of LRRK2 G2019S sub-cohorts to sPD and HC

Cohort

1

2

3

4

    
 

G2019S + PD n = 134

G2019S + NMC n = 182

sPD n = 379

HC n = 190

P Value 1 vs 2

P Value 1 vs 3

P Value 2 vs 4

P Value 3 vs 4

Age (years), mean (SD)a

63.26 (9.20)

62.33 (7.72)

61.94 (9.66)

60.67 (11.16)

    

Age at onset (years), mean (SD)

58.05 (9.99)

 

59.94 (9.93)

 

N/A

0.0609

N/A

N/A

Mean Striatal DaT SBR, mean (SD)

missing

1.29 (0.38)

2.52 (0.52)

1.39 (0.39)

2.57 (0.56)

<0.0001

0.0093

0.4164

<0.0001

15

9

4

3

Disease duration (months), median

(range)

28.55

 

4.2

 

N/A

<0.0001α

N/A

N/A

(0.97, 104.43)

(0.40, 35.83)

Female Sex, n (%)

65 (48.51%)

104 (57.14%)

129 (34.04%)

67 (35.26%)

0.1283

0.0030

<0.0001

0.7716

MDS-UPDRS III Off, mean (SD)

missing

22.46 (11.45)

3.14 (4.11)

20.89 (8.79)

1.19 (2.15)

<0.0001

0.2097

<0.0001

<0.0001

36

0

0

2

MoCA, median (range)

missing

27

27

28

28

0.2689α

0.0010α

<0.0001α

<0.0001α

(13.00, 30.00)

(18.00, 30.00)

(17.00, 30.00)

(26.00, 30.00)

2

1

0

0

Total di-18:1-BMP, median (range)

12.60

13.88

3.53

3.77

0.2246

<0.0001

<0.0001

0.8823

(1.29, 160.95)

(0.90, 71.97)

(0.21, 38.02)

(0.39, 22.03)

Total di-22:6-BMP, median (range)

65.63

63.79

10.61

10.42

0.8082

<0.0001

<0.0001

0.5976

(9.85, 307.69)

(8.65, 245.60)

(1.18, 76.76)

(1.25, 85.89)

2,2’-di-22:6-BMP, median (range)

51.39

49.38

6.83

6.37

0.9820

<0.0001

<0.0001

0.6946

(6.22, 240.68)

(6.99, 248.17)

(0.81, 59.27)

(0.60, 65.96)

b Comparison of LRRK2 R1441G sub-cohorts to sPD, and HC

Cohort

1

2

3

4

   
 

R1441G + PD n = 15

R1441G + NMC n = 15

sPD n = 379

HC n = 190

P Value 1 vs 2

P Value 1 vs 3

P Value 2 vs 4

Age (years), mean (SD)

64.51 (10.46)

56.82 (5.09)

61.94 (9.66)

60.67 (11.16)

0.0186

0.3650

0.0192

Age at onset (years), mean (SD)

60.70 (11.74)

 

59.94 (9.93)

 

N/A

0.8069

N/A

Mean Striatal DaT SBR, mean (SD)

missing

1.37 (0.33)

2.64 (0.68)

1.39 (0.39)

2.57 (0.56)

<0.0001

0.7551

0.7039

0

0

4

3

Disease duration (months), median

(range)

24.8

 

4.2

 

N/A

<0.0001α

N/A

(4.10, 77.80)

(0.40, 35.83)

Female Sex, n (%)

11 (73.33%)

10 (66.67%)

129 (34.04%)

67 (35.26%)

0.6903

0.0018

0.0156

MDS-UPDRS III Off, mean (SD)

missing

15.86 (5.57)

2.29 (3.31)

20.89 (8.79)

1.19 (2.15)

<0.0001

0.0053

0.2421

1

1

0

2

MoCA, median (range)

missing

25

28

28

28

0.0494α

0.0011α

0.0812α

(18.00, 30.00)

(22.00, 30.00)

(17.00, 30.00)

(26.00, 30.00)

0

0

0

0

Total di-18:1-BMP, median (range)

14.25

22.65

3.53

3.77

0.3133

<0.0001

<0.0001

(5.04, 39.26)

(5.40, 72.51)

(0.21, 38.02)

(0.39, 22.03)

Total di-22:6-BMP, median (range)

71.52

47.27

10.61

10.42

0.3584

<0.0001

<0.0001

(30.90, 136.67)

(19.15, 121.85)

(1.18, 76.76)

(1.25, 85.89)

2,2’-di-22:6-BMP, median (range)

49.43

36.29

6.83

6.37

0.2203

<0.0001

<0.0001

(17.82, 116.30)

(11.50, 101.43)

(0.81, 59.27)

(0.60, 65.96)

  1. Pairwise comparisons that showed significance at p value <0.0125 (after Bonferroni correction applied due to multiple comparison) are shown in bolded font.
  2. PD Parkinson’s disease, NMC non-manifesting carriers, sPD sporadic PD, HC healthy control, SD standard deviation, DaT dopamine transporter, SBR specific binding ratio, MDS-UPDRS movement disorders society-unified Parkinson’s disease rating scale, MoCA Montreal cognitive assessment, BMP bis(monoacylglycerol)phosphate.
  3. αComputed using Mann–Whitney U-test.
  4. aThe overall F-test was non-significant thus pairwise comparisons were not computed.
Back to article page